中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
5期
595-597
,共3页
项贤者%郑昌爱%姜俊%黄汉津%叶建孟
項賢者%鄭昌愛%薑俊%黃漢津%葉建孟
항현자%정창애%강준%황한진%협건맹
便秘%精神分裂症%氯氮平%聚乙烯二醇类%乳果糖
便祕%精神分裂癥%氯氮平%聚乙烯二醇類%乳果糖
편비%정신분렬증%록담평%취을희이순류%유과당
Constipation%Schizophrenia%Clozapine%Polyethylene glycols%Lactulose
目的 探讨聚乙二醇3350电解质散治疗精神分裂症患者使用氯氮平诱发便秘的有效性和安全性.方法 使用氯氮平治疗后出现便秘的精神分裂症患者150例,随机进入聚乙二醇组、乳果糖组和按需导泻组,每组各50例,分别予以聚乙二醇3350电解质散13.7 g,2次/d;乳果糖口服液10 ml,3次/d;按需导泻组不予定期缓泻剂,只是按需予以导泻治疗;观察6周,包括2周的基线观察期、4周治疗期.评估标准:对便秘患者的全部症状进行总体评估,对患者的每个便秘参数及安全性进行评估.结果 治疗4周后聚乙二醇组、乳果糖组、按需导泻组总有效率分别为90.0%、68.0%、38.0%,差异均有统计学意义(均P＜0.05);各组大便形态正常率分别为84.0%、60.0%、28.0%.聚乙二醇组在首次排便时间、每周平均排便次数等方面优于其它两组及基线期,同时在治疗前后大便伴随症状积分改善方面明显优于其它组.在安全性比较中,各组治疗前后的肝肾功能、电解质、血糖、心电图、精神分裂症症状潘氏评分等均无发生明显改变(P＞0.05);各组无明显的不良反应发生.结论 聚乙二醇3350电解质散治疗精神分裂症患者氯氮平诱发的慢性便秘安全、有效.
目的 探討聚乙二醇3350電解質散治療精神分裂癥患者使用氯氮平誘髮便祕的有效性和安全性.方法 使用氯氮平治療後齣現便祕的精神分裂癥患者150例,隨機進入聚乙二醇組、乳果糖組和按需導瀉組,每組各50例,分彆予以聚乙二醇3350電解質散13.7 g,2次/d;乳果糖口服液10 ml,3次/d;按需導瀉組不予定期緩瀉劑,隻是按需予以導瀉治療;觀察6週,包括2週的基線觀察期、4週治療期.評估標準:對便祕患者的全部癥狀進行總體評估,對患者的每箇便祕參數及安全性進行評估.結果 治療4週後聚乙二醇組、乳果糖組、按需導瀉組總有效率分彆為90.0%、68.0%、38.0%,差異均有統計學意義(均P＜0.05);各組大便形態正常率分彆為84.0%、60.0%、28.0%.聚乙二醇組在首次排便時間、每週平均排便次數等方麵優于其它兩組及基線期,同時在治療前後大便伴隨癥狀積分改善方麵明顯優于其它組.在安全性比較中,各組治療前後的肝腎功能、電解質、血糖、心電圖、精神分裂癥癥狀潘氏評分等均無髮生明顯改變(P＞0.05);各組無明顯的不良反應髮生.結論 聚乙二醇3350電解質散治療精神分裂癥患者氯氮平誘髮的慢性便祕安全、有效.
목적 탐토취을이순3350전해질산치료정신분렬증환자사용록담평유발편비적유효성화안전성.방법 사용록담평치료후출현편비적정신분렬증환자150례,수궤진입취을이순조、유과당조화안수도사조,매조각50례,분별여이취을이순3350전해질산13.7 g,2차/d;유과당구복액10 ml,3차/d;안수도사조불여정기완사제,지시안수여이도사치료;관찰6주,포괄2주적기선관찰기、4주치료기.평고표준:대편비환자적전부증상진행총체평고,대환자적매개편비삼수급안전성진행평고.결과 치료4주후취을이순조、유과당조、안수도사조총유효솔분별위90.0%、68.0%、38.0%,차이균유통계학의의(균P＜0.05);각조대편형태정상솔분별위84.0%、60.0%、28.0%.취을이순조재수차배편시간、매주평균배편차수등방면우우기타량조급기선기,동시재치료전후대편반수증상적분개선방면명현우우기타조.재안전성비교중,각조치료전후적간신공능、전해질、혈당、심전도、정신분렬증증상반씨평분등균무발생명현개변(P＞0.05);각조무명현적불량반응발생.결론 취을이순3350전해질산치료정신분렬증환자록담평유발적만성편비안전、유효.
Objective To explore the efficacy and safety of Polyethylene glycol 3350 plus electrolyte bulk on the schizophrenia patients with constipation induced by clozapine. Methods 150 cases of schizophrenia inpatient and outpatient with constipation induced by clozapine treatment were selected and randoly dirided into the group of polyethylene glycol,lactulose group and non-intervention group with 50 patients in each group and each patient or their families signed the informed consent. The treatment groups took orally with Polyethyle ne glycol 3350 plus electrolyte 13. 7grams,2 times per day and lactulose oral solution 10ml,3 times per day respectively. The non-intervention group was not given a regular basis laxatives, but with cathartic therapy in demand. The period of experiment was 6 weeks including 2 weeks baseline observation period and 4 weeks treatment. Assessment criteria: an overall assessment of all symptoms of patients and each patient's constipation and safety parameters were assessed. Results After treatment for 4 weeks,the total effective rate in three groups was 90.0% ,68.0% ,38.0% (all P ＜0.05). The difference was statistically significant. The normal shape of stool rate was 84.0% ,60.0% ,28.0%. PEG group were better than the other 2 groups at baseline in the first defecation time,the average times of bowel movements per week,theutilization of laxatives during treatment, while symptom score improvement in the stool was significantly better than other groups after treatment. The safety parameters including liver and kidney function, lectrolytes, glucose, ECG, symptoms of schizophrenia such as PANSS score had no obvious change in each group after treatment. Conclusion PEG 3350 plus electrolytes was effective and safe in the treatment of clozapine-indueed constipation in chronic schizophrenia.
